Oxford BioMedica CEO To Hire More People, Expects More Deals Following Gene Therapy Pact With Axovant

06 Jun 2018

• By Sten Stovall

Britain's Oxford BioMedica has signed a $842m deal with US-based Axovant Sciences to commercialize its next generation gene therapy for Parkinson's disease.

Parkinsons — Duo Aim To Develop And Commercialize OXB-102 Using Oxford BioMedica's LentiVector Platform • Source: Shutterstock

Oxford BioMedica CEO To Hire More People, Expects More Deals Following Gene Therapy Pact With Axovant

More from Deals

More from Business